Peptides for Muscle Growth: Evidence-Based Guide

The most-studied peptides for muscle growth target the body's growth-hormone (GH) and IGF-1 axes, or block myostatin (a negative regulator of muscle mass). The evidence ranges from FDA-approved drugs with decades of clinical data (HGH, Tesamorelin) to research-use compounds with primarily animal data (Follistatin-344, ACE-031). The realistic expectation: meaningful but moderate body-composition shifts with disciplined training and nutrition; not steroid-tier hypertrophy. This guide covers the major options, what each does, and how to compare them.

For the full per-peptide profiles, see Ipamorelin, CJC-1295, MK-677, Hexarelin, Sermorelin, Tesamorelin, and the muscle-growth hub.

The biology in one paragraph

Muscle growth requires a positive net protein balance over time. The hormones that drive that balance — testosterone, growth hormone, IGF-1, insulin — are downstream of training stimulus and nutritional intake. Peptides intervene by pushing GH or IGF-1 levels higher (most commonly), by blocking myostatin (which normally caps muscle accumulation), or by directly supplying GH or IGF-1. They are adjuvants, not replacements for training stimulus.

The major options

Growth hormone secretagogues (GHS)

These stimulate the body's own pituitary GH release. Two mechanistic sub-classes:

GHRH analogs — mimic growth-hormone-releasing hormone:

• Sermorelin — short-acting GHRH analog. Mild GH pulse.
• CJC-1295 — modified GHRH. Two variants: without DAC (short-acting, dosed with GHRPs) and with DAC (long-acting, days of activity per dose).
• Tesamorelin — FDA-approved GHRH analog for HIV lipodystrophy; off-label for body composition.

GHRPs (growth hormone releasing peptides) — work through the ghrelin receptor:

• Ipamorelin — selective; minimal cortisol or prolactin spike. Most commonly stacked with CJC-1295.
• Hexarelin — stronger pulse than Ipamorelin; mild cortisol/prolactin elevation.
• GHRP-2, GHRP-6 — older GHRPs; GHRP-6 also stimulates hunger strongly.
• MK-677 (Ibutamoren) — oral, non-injectable GHS. Sustained GH/IGF-1 elevation; appetite increase; fluid retention.

The GHRH + GHRP combination (e.g., CJC-1295 without DAC + Ipamorelin) produces a larger pulse than either alone. See the comparison article for the mechanism details.

IGF-1 analogs

Supply IGF-1 directly or in a modified form:

• IGF-1 LR3 — long-acting (Long R3) IGF-1 analog; ~50× longer half-life than native IGF-1.
• IGF-1 DES — truncated (Des(1-3)) IGF-1; reduced binding-protein affinity, more local availability.
• MGF (Mechano Growth Factor) — IGF-1 splice variant produced in muscle in response to mechanical loading.

Used primarily in research; clinical-use data limited.

Myostatin inhibitors

Block myostatin, the body's normal cap on muscle accumulation:

• ACE-031 (ACVR2B-Fc) — soluble receptor that traps myostatin. Phase 2 trials ended for off-target effects.
• Follistatin-344 — natural myostatin inhibitor; some animal data, very limited human data.

This class is the most speculative of the muscle-growth peptides. Promising mechanism but the human data is not yet there.

Direct GH

• HGH (Somatropin) — FDA-approved recombinant human growth hormone. Decades of clinical data for diagnosed GH deficiency. Off-label "anti-aging" use is not FDA-approved and is illegal to prescribe in the US for that indication. The body-composition signal (more lean mass, less fat mass) is real and well-characterized at clinical doses; supraphysiologic doses carry higher cumulative risk.

How they compare

	GHRH analogs (Sermorelin/CJC-1295)	GHRPs (Ipa/Hex/GHRP-2/6)	MK-677 (oral)	IGF-1 LR3/DES	HGH	Myostatin inhibitors
Mechanism	Pituitary GH release via GHRH receptor	Pituitary GH release via ghrelin receptor	Same as GHRPs but oral	Direct IGF-1 supply	Direct GH supply	Block myostatin
Approval	Sermorelin & Tesamorelin FDA-approved	Research-use	Research-use (oral)	Research-use	FDA-approved for deficiency	Research only
Route	SC injection	SC injection	Oral	SC injection	SC injection	SC injection
Frequency	Daily or 2–3×/day	Daily or 2–3×/day	Daily (oral)	Daily	Daily	Weekly
Stack with	A GHRP (synergistic)	A GHRH analog (synergistic)	Standalone	Often standalone	Often standalone	Standalone
Common SE	Mild; flushing	Mild; cortisol bump for Hex/GHRP-2	Water retention, appetite, glucose elevation	Hypoglycemia risk	Joint discomfort, water retention	Off-target effects in trials
Human evidence	Strong for approved indications	Moderate	Decade+ of trials	Limited	Strongest	Limited

What to expect

• Lean mass change at responsive doses across 12–24 weeks: 1–4 kg additional lean mass on top of training-driven baseline, depending on training experience, nutrition, and compound.
• Fat mass change at the same window: modest reduction (1–3 kg), driven by GH/IGF-1 mobilization of fatty acids.
• Recovery improvement is often the more clinically visible effect than mass change — faster soreness clearance, more training capacity per week.
• Sleep quality improves for many users on GH-axis peptides (the natural nocturnal GH pulse is amplified).
• Joint discomfort and water retention are common at higher doses; usually resolves within 2 weeks of dose reduction.

These are not steroid-tier numbers. The expectation should be "a useful adjuvant to training," not "transformation in 12 weeks."

Cycle design

Standard pattern for GH-axis peptides:

• Loading (rare): not commonly used.
• Maintenance: 8–12 weeks at clinical dose.
• Washout: 4 weeks. Receptor re-sensitization; baseline reassessment.

See peptide cycling for the full framework.

Safety considerations

• Cortisol / prolactin — GHRP-2 and Hexarelin can elevate both. Ipamorelin avoids this.
• Glucose — MK-677 long-term can elevate fasting glucose; monitor A1C at 12-week intervals if you cycle MK-677 for more than 8 weeks.
• Fluid retention and joint discomfort — common across the GH-axis class. Lower the dose if they appear.
• Carpal tunnel-like numbness — high-dose HGH or supraphysiologic GH stacking. Stop the dose, the numbness resolves.
• IGF-1 / insulin overlap — IGF-1 LR3 in particular can produce hypoglycemia if dosed too aggressively pre-meal. Dose post-workout with a meal.
• Cancer-history exclusion — IGF-1 promotes growth signaling generally. Anyone with a personal or family cancer history should not run these without explicit oncology sign-off.

See peptide side effects and are peptides safe? for the full safety frame.

How to choose

A decision frame:

• First-time peptide user, want a sane starting place? CJC-1295 (without DAC) + Ipamorelin stack, 8–12 weeks, with bloodwork before and after.
• Want simplicity and oral dosing? MK-677. Watch glucose, manage appetite.
• Want maximum GH pulse? Hexarelin + Tesamorelin or CJC-1295 — accept the higher side-effect risk.
• Recovering from an injury rather than building mass? Healing peptides may fit better — see BPC-157 vs TB-500 and the healing hub.
• Cutting (lean mass preservation during weight loss)? GH-axis pairs with GLP-1 weight loss reasonably well clinically, but stack-safety data is limited. Discuss with a clinician.

Where to go from here

• Browse the muscle-growth hub for the ranked peptide list.
• Use the calculator for dose math.
• Read how to use peptides, how to inject peptides, and peptide cycling for the operational guides.
• Get the safety frame in are peptides safe?.

This article is informational, not medical advice. GH-axis manipulation requires clinician supervision in any responsible protocol.